Practice of Monitoring Cisplatin-Induced Ototoxicity by Audiology, ENT, and Oncology Specialists: A Survey-Based Study in a Single Italian Medical Center

Overview

Journal Audiol Res

Publisher MDPI

Specialty Otorhinolaryngology

Date 2023 Oct 27

PMID 37887850

Authors

Valeria Gambacorta

Eva Orzan

Mario Faralli

Mario Gulla

Ruggero Lapenna

Irene Baietta

Verena De Angelis

Giampietro Ricci

Affiliations

Soon will be listed here.

Abstract

Ototoxic drugs can result in hearing loss and tinnitus. Early detection of the ototoxic process can help minimize or prevent these consequences. The American Speech-Language-Hearing Association has provided guidelines for monitoring ototoxicity, whereas Italy has not yet implemented a national monitoring protocol. This study aims to assess the current state of ototoxicity monitoring in patients receiving cisplatin therapy. A self-administered survey has been used to gather information from oncologists, audiologists, and ENT specialists. The research was conducted at Santa Maria della Misericordia hospital in Perugia. Two questionnaires were administered, one to ENT/audiology specialists and another to oncology specialists. Both questionnaires were used to collect information on awareness of chemotherapy-induced ototoxicity. A comprehensive understanding of cisplatin-induced ototoxicity has been widely established (100%). The most commonly reported audiological symptoms by patients were hearing loss (100%) and tinnitus (87.5%). The majority of ENT and audiologists (93.8%) and oncologists (92.9%) expressed the need for a specific ototoxic monitoring program. However, they noted the absence of a well-defined ototoxicity monitoring protocol. A well-established and efficient ototoxic monitoring system facilitates early detection of ototoxic hearing loss and subsequent rehabilitation of inevitable hearing impairment.

References

Beck A, Maurer J, Welkoborsky H, Mann W . [Changes in transitory evoked otoacoustic emissions in chemotherapy with cisplatin and 5FU]. HNO. 1992; 40(4):123-7. View

Fausti S, Frey R, Henry J, Olson D, Schaffer H . Early detection of ototoxicity using high-frequency, tone-burst-evoked auditory brainstem responses. J Am Acad Audiol. 1992; 3(6):397-404. View

Jacobson G, Newman C, Hunter L, Balzer G . Balance function test correlates of the Dizziness Handicap Inventory. J Am Acad Audiol. 1991; 2(4):253-60. View

Paken J, Govender C, Pillay M, Sewram V . A Review of Cisplatin-Associated Ototoxicity. Semin Hear. 2019; 40(2):108-121. PMC: 6486385. DOI: 10.1055/s-0039-1684041. View

Knight K, Kraemer D, Winter C, Neuwelt E . Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol. 2007; 25(10):1190-5. DOI: 10.1200/JCO.2006.07.9723. View

Santucci N, Garber B, Ivory R, Kuhn M, Stephen M, Aizenberg D . Insight into the current practice of ototoxicity monitoring during cisplatin therapy. J Otolaryngol Head Neck Surg. 2021; 50(1):19. PMC: 7995701. DOI: 10.1186/s40463-021-00506-0. View

Durrant J, Rodgers G, Myers E, Johnson J . Hearing loss--risk factor for cisplatin ototoxicity? Observations. Am J Otol. 1990; 11(5):375-7. View

Fausti S, Henry J, Schaffer H, Olson D, Frey R, Bagby Jr G . High-frequency monitoring for early detection of cisplatin ototoxicity. Arch Otolaryngol Head Neck Surg. 1993; 119(6):661-6. DOI: 10.1001/archotol.1993.01880180081015. View

Paken J, Govender C, Pillay M, Sewram V . Perspectives and practices of ototoxicity monitoring. S Afr J Commun Disord. 2020; 67(1):e1-e10. PMC: 7276482. DOI: 10.4102/sajcd.v67i1.685. View

10.

Paken J, Govender C, Pillay M, Sewram V . Cisplatin-associated ototoxicity: perspectives from a single institution cervical cancer cohort and implications for developing a locally responsive monitoring programme in a public healthcare setting. BMC Health Serv Res. 2022; 22(1):791. PMC: 9206275. DOI: 10.1186/s12913-022-08099-8. View

11.

Konrad-Martin D, Poling G, Garinis A, Ortiz C, Hopper J, OConnell Bennett K . Applying U.S. national guidelines for ototoxicity monitoring in adult patients: perspectives on patient populations, service gaps, barriers and solutions. Int J Audiol. 2017; 57(sup4):S3-S18. PMC: 6450095. DOI: 10.1080/14992027.2017.1398421. View

12.

Ganesan P, Schmiedge J, Manchaiah V, Swapna S, Dhandayutham S, Kothandaraman P . Ototoxicity: A Challenge in Diagnosis and Treatment. J Audiol Otol. 2018; 22(2):59-68. PMC: 5894487. DOI: 10.7874/jao.2017.00360. View

13.

Rizk H, Lee J, Liu Y, Endriukaitis L, Isaac J, Bullington W . Drug-Induced Ototoxicity: A Comprehensive Review and Reference Guide. Pharmacotherapy. 2020; 40(12):1265-1275. DOI: 10.1002/phar.2478. View

14.

Baguley D, Prayuenyong P . Looking beyond the audiogram in ototoxicity associated with platinum-based chemotherapy. Cancer Chemother Pharmacol. 2019; 85(2):245-250. PMC: 7015967. DOI: 10.1007/s00280-019-04012-z. View

15.

Ahmed M, Mishra A, Sawlani K, Verma V, Garg R, Singh H . Clinical Predictors of Streptomycin-Vestibulotoxicity. Indian J Otolaryngol Head Neck Surg. 2016; 68(3):359-66. PMC: 4961644. DOI: 10.1007/s12070-015-0949-x. View

16.

Watts K . Ototoxicity: Visualized in Concept Maps. Semin Hear. 2019; 40(2):177-187. PMC: 6486390. DOI: 10.1055/s-0039-1684046. View

17.

Maru D, Malky G . Current practice of ototoxicity management across the United Kingdom (UK). Int J Audiol. 2018; 57(sup4):S76-S88. DOI: 10.1080/14992027.2018.1460495. View

18.

Tusa R . Bedside assessment of the dizzy patient. Neurol Clin. 2005; 23(3):655-73, v. DOI: 10.1016/j.ncl.2005.03.001. View